Bicyclic inhibitors of histone deacetylase

• US 10,696,673 B2
• Filed: 11/12/2019
• Issued: 06/30/2020
• Est. Priority Date: 01/11/2017
• Status: Active Grant

• Current Assignee: Alkermes Pharma Ireland Limited (Alkermes plc)
• Original Assignee: Rodin Therapeutics, Inc. (Alkermes Incorporated)
• Inventors: Fuller, Nathan Oliver, Lowe, III, John A.
• Primary Examiner(s): Ramachandran, Umamaheswari
• Application Number:
  US16/681,213
• Publication Number:
  US 20200148678A1
• Time in Patent Office: 231 Days
• CPC Class Codes: A61K 31/437 the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

Claims

1. A compound of the formula:

3. A method of inhibiting HDAC activity in a subject comprising the step of administering to the subject in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of the formula: